A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 165 participants.
Also called NCT07023614
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 165 participants
- Sponsor
- Imbria Pharmaceuticals, Inc.
- Registry
-
NCT07023614
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07023614. Randomized; triple masking; primary purpose treatment. Start 2025-10-06 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Acronym
- FORTITUDE-HCM
- Condition
- Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Ninerafaxstat 200mg MR
- Intervention (Drug)
- Placebo
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct07023614- Content hash
76d3aa8311515692b73c0e8a38f654437f4b645ee1a1559d16af9f00f7e4b72d